NCT04958304 is a clinical trial in SARS-CoV-2, sponsored by ModernaTX, Inc..

Who is sponsoring NCT04958304?

NCT04958304 is sponsored by ModernaTX, Inc..

What condition does NCT04958304 study?

NCT04958304 studies SARS-CoV-2.

Is NCT04958304 still recruiting?

NCT04958304 is currently terminated. Last updated 28 November 2023.

Last reviewed 2023-11-28 · How we verify

NCT04958304

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Moderna COVID-19 Vaccine mRNA-1273 Observational Pregnancy Outcome Study

Terminated Last updated 28 November 2023

What this trial tests

trial in SARS-CoV-2 in 20 participants. Terminated before completion.

Timeline

1 September 2021

Primary endpoint
22 September 2023

22 September 2023

Quick facts

Lead sponsor	ModernaTX, Inc.
Status	Terminated
Study type	OBSERVATIONAL
Enrollment	20
Start date	1 September 2021
Primary completion	22 September 2023
Estimated completion	22 September 2023
Sites	1 location across United States

Conditions studied

SARS-CoV-2 — all drugs for SARS-CoV-2 →

Sponsor

ModernaTX, Inc. — full company profile →

Who can join

18 and older, female only, with SARS-CoV-2. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The main goal of this study is to evaluate the outcomes of pregnancy in females exposed to the Moderna COVID-19 vaccine (mRNA-1273) during pregnancy.

Publications & conference data

6 peer-reviewed publications reference this trial (live from Europe PMC):

The Development of mRNA Vaccines for Infectious Diseases: Recent Updates.
Nitika, Wei J, Hui AM. · · 2021 · cited 27× · PMID 34916811 · DOI 10.2147/idr.s341694
Alignment of national COVID-19 vaccine recommendations for pregnant and lactating women.
Giles ML, Gunatilaka A, Palmer K, Sharma K, et al · · 2021 · cited 24× · PMID 34621092 · DOI 10.2471/blt.21.286644
COVID-19 disease and vaccination in pregnant and lactating women.
Safadi MAP, Spinardi J, Swerdlow D, Srivastava A. · · 2022 · cited 18× · PMID 35452552 · DOI 10.1111/aji.13550
Associations of COVID-19 vaccination during pregnancy with adverse neonatal and maternal outcomes: A systematic review and meta-analysis.
Ding C, Liu Y, Pang W, Zhang D, et al · · 2023 · cited 17× · PMID 36794075 · DOI 10.3389/fpubh.2023.1044031
Addressing COVID-19 vaccine hesitancy.
Kassianos G, Puig-Barberà J, Dinse H, Teufel M, et al · · 2022 · cited 14× · PMID 35814493 · DOI 10.7573/dic.2021-12-3
A Brighton Collaboration standardized template with key considerations for a benefit/risk assessment for the Moderna COVID-19 Vaccine (mRNA-1273).
Leav B, Straus W, White P, Leav A, et al · · 2022 · cited 4× · PMID 35753841 · DOI 10.1016/j.vaccine.2022.06.005

Verify or expand the search:

Other recruiting trials for SARS-CoV-2

Currently open trials in the same condition.

NCT07266558 — A Study to Evaluate the Efficacy and Safety of mRNA-1283 and mRNA-1273 in Participants 50 to 64 Years of Age Without Hig · Phase 4 · recruiting
NCT06684379 — Study on Safety and Efficacy of Two Doses of PRS CK STORM in the Modulation of the Cytokine Storm for the Treatment of A · Phase 1, PHASE2 · recruiting
NCT06585241 — A Study to Investigate the Immunogenicity and Safety of mRNA COVID-19 Variant-containing Vaccine Formulations · Phase 4 · recruiting
NCT05876377 — Use and Effectiveness of COVID-19 Vaccines Using State Vaccine Registries and Insurance Claims Data · active not recruiting
NCT05799651 — Safety and Immunogenicity of Glycovax-002 Vaccine in Healthy Adults · Phase 1 · active not recruiting

Other ModernaTX, Inc. trials

Trials by the same sponsor.

NCT07496450 — A Study of mRNA-1018-H5 Pandemic Influenza Vaccine in Healthy Adults · Phase 3 · recruiting
NCT07478952 — A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189 in Healthy Adults 18 to 30 Years of Age · Phase 1 · recruiting
NCT07266558 — A Study to Evaluate the Efficacy and Safety of mRNA-1283 and mRNA-1273 in Participants 50 to 64 Years of Age Without Hig · Phase 4 · recruiting
NCT07116616 — A Study of mRNA-2808 in Participants With Relapsed or Refractory Multiple Myeloma · Phase 1, PHASE2 · recruiting
NCT07117487 — A Study of mRNA-1345 Following a Primary Dose of a Licensed Protein Subunit Respiratory Syncytial Virus (RSV) Vaccine in · Phase 3 · active not recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04958304 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by ModernaTX, Inc.
Last refreshed: 28 November 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04958304.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing